Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. [electronic resource]
Producer: 20191119Description: 2749-2757 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Angiopoietin-2 -- antagonists & inhibitors
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab -- administration & dosage
- Carboplatin -- administration & dosage
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Neoplasms -- diagnosis
- Paclitaxel -- administration & dosage
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.